
Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

